VISCHER advises Okairos and selling shareholders (including BioMedInvest, LSP, Novartis Venture Funds) in the sale of Okairos AG, a Swiss developer of vaccine technologies, to GlaxoSmithKline Plc for EUR 250 Mio. The team at VISCHER is led by Matthias Staehelin (Corporate), Nadia Tarolli (Tax) with Roberto Peduzzi, Melanie Knüsel and Eric Flückiger.